For the first time, a drug appears to have a slowing effect - though limited - on the progression from mild cognitive impairment, a memory disorder considered a strong early predictor of Alzheimer's disease, to Alzheimer's. This randomized, dou
Statins, drugs widely used to lower cholesterol in patients with heart disease, may also help prevent memory loss connected to dementia or Alzheimer's disease, say researchers at the University of Alabama at
Established pharmacists as well as those studying to gain their qualifications will benefit from a new book which focuses on pharmaceutical care in New Zealand.From Clinical Pharmacy to Pharmaceutical Care, edited by Associate-Professor Patrick
ARICEPT? a popular Alzheimer's drug has been shown to delay the onset of the disease among people with mild cognitive impairment.ARICEPT? (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically a
An article in the July issue of the Archives of Neurology reports that the drugs levodopa and pramipexole both appear to be reasonable options as initial therapy for Parkinson disease, but they
An article in the July issue of the Archives of Dermatology reports that Melanotan-1, a synthetic agent similar to the body's hormone that regulates skin pigmentation, can be combined with UV-B
The Food and Drug Administration (FDA) is proposing to change the new and generic drug review processes by replacing "approvable letters" and "not approvable letters" with "complete response letters" that provide companies with specific information abo
If you want to increase your chances of living longer, taking cholesterol drugs is an easy way to do it. That's the message from a Harvard study of 4,162 people hospitalized in 350 places in eight countries. It is the first research to show that intense
One expert questions the acceptability of the current level of acetaminophen-related injury and death, while another suggests that acetaminophen overdoses are misunderstood.Acetaminophen overdose causes more than 450 deaths due to acute liver f
Neuro3d, a biopharmaceutical company focused on drug discovery and development, announced today that Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) in Beerse, Belgium,
The data, drawn from the recently completed Renagel in New Dialysis (RIND) study, compare the clinical experiences of new dialysis patients on Renagel with those on calcium-based phosphate binders for a period of 18 months.
Investigators will report during a symposium at the American Society of Nephrology meeting in St. Louis that the RIND study data show a significant difference in the primary endpoint -- change in coronary artery calcification over 18 months -- between patients using calcium-based phosphate binders and those using Renagel. Results show that the change in coronary artery calcification scores was significantly greater in the calcium-based phosphate binder group than in the Renagel group.
The RIND data also show that, consistent with the findings of the earlier Treat-to-Goal study, patients using both types of phosphate binders were able to achieve target levels for phosphorus and calcium-phosphorus product as outlined in the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines.
Full data will be submitted for publication in a peer-reviewed medical journal.
"The preliminary results we have seen in the RIND study underscore Renagel's role as a first-line treatment option for patients beginning dialysis," said principal investigator Geoffrey Block, M.D., of Denver Nephrologists, PC, Denver, Colorado. "This study shows that by using Renagel from the time they begin dialysis, patients can achieve the K/DOQI targets for phosphorus and calcium-phosphorus product -- with a significantly lower progression of coronary artery calcification than with calcium-based phosphate binders."
The Genzyme-funded RIND study is a randomized, open-label trial that involved 129 patients who were new to dialysis. Investigators evaluated patients for coronary artery calcification at baseline and at six, 12, and 18 months using electron beam computed tomography.
The clinical impact of the coronary artery calcification scores -- including the differences noted between treatment groups -- has not been demonstrated. Through the Dialysis Clinical Outcomes Revisited (D-COR(SM)) trial, investigators are currently examining the difference in morbidity and mortality outcomes for patients receiving Renagel and those receiving calcium- based phosphate binders. The first results are expected from this study in mid-2005.
Renagel helps to control serum phosphorus in patients with Chronic Kidney Disease on hemodialysis. The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a first-line treatment option to reduce phosphorus. Renagel is the only phosphate binder available that does not contain either calcium or a metal. It has an established safety profile, is not systemically absorbed and provides phosphorus control without concerns of calcium or metal accumulation.
http://www.genzyme.com/